China's Supreme People's Court has permitted British-Swedish pharma company AstraZeneca, or AZ, to withdraw a lawsuit from the top court, after judges refrained from concluding that a pay-for-delay patent agreement at the center of the dispute violates the country's antitrust law.AstraZeneca initially appealed to the top court a decision by the Nanjing